Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Dose Comparison Study to Assess the Efficacy of MBM-02 (Tempol) as a Treatment for Patients Diagnosed With Prostate Cancer in Biochemical Recurrence

NCT04876755 is registered in ClinicalTrials.gov with Matrix Biomed, Inc. as lead sponsor.

NCT NCT04876755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04876755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Dose Comparison Study to Assess the Efficacy of MBM-02 (Tempol) as a Treatment for Patients Diagnosed With Prostate Cancer in Biochemical Recurrence
Lead sponsor
Matrix Biomed, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
May 30, 2021
Completion date
February 28, 2023
Enrollment
55 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biochemical recurrent prostate cancer, prostate cancer recurrent